People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-generation, Omicron-targeted vaccines expected in the fall, five vaccine experts told Reuters.

The BA.5 subvariant of Omicron was estimated to make up 81.9% of the circulating coronavirus variants in the United States for the week ended July 23, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.

Johnson & Johnson on Tuesday reported quarterly results that beat analysts’ estimates on strong demand for cancer drug Darzalex and its COVID-19 vaccine, even as the company cut its full-year adjusted profit forecast due to a stronger dollar.

The European Medicines Agency on Monday started reviewing a low-dose version of BioNTech and Pfizer’s COVID-19 vaccine for use in children between the age of six months and four years.

The European Medicines Agency on Thursday identified severe allergic reactions as potential side effects of Novavax Inc.’s COVID-19 vaccine.

Canada has approved Moderna Inc.’s COVID-19 vaccine for children aged 6 months and older, according to information posted on the government’s website.

Pfizer Inc. and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.

U.S. Food and Drug Administration staff reviewers on Friday said Moderna Inc.’s COVID-19 vaccine appears safe and effective for use in children aged 6 months to 17 years old as a committee of scientists will meet next week to vote on whether to recommend the regulator authorize the vaccine in children.